AI Science Tracker

CHIEF: detecting cancer and predicting survival from slides

Harvard Medical School · 4 Sep 2024 · medicine

Discovery

CHIEF: detecting cancer and predicting survival from slides

Trained on 15 million patches and 60,000 slides and tested on more than 19,400 slides from 32 datasets and 24 hospitals: it detects cancer with about 94% accuracy across 15 datasets, predicts mutations in 54 genes with over 70% accuracy, and improves survival prediction by 8% across 17 institutions. Retrospective validation; not trained on rare diseases or premalignant tissue.

Technology: CHIEF (pathology foundation model)

Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.

Result, AI contribution and limits

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

  • Publication status: Peer-reviewed paper
  • Test type: retrospective or benchmark
  • Tested: Retrospective validation on more than 19,400 slides from 32 datasets at 24 hospitals; cancer detection was about 94% accurate across datasets.
  • Still unknown: Validation beyond these datasets is still needed, rare and non-cancerous conditions and pre-malignant tissue were not tested, and gene prediction accuracy varies by gene and cancer type.
  • AI role: Read digital tumor slides to detect cancer, predict gene mutations and survival, and generate heat maps of tissue features for pathologists.

Evidence sources: https://hms.harvard.edu/news/new-artificial-intelligence-tool-cancer

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: press release. Paper: linked separately.

Review scope and date are not recorded; source checked does not establish full-text review.

Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 685 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.

Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Follow-up and relationships

No follow-up recorded; this is not a claim that no follow-up exists.

Follow-up review scope and date are not recorded.

No source-supported relationships recorded.

Open in the full catalog for filters, charts and related discoveries.